Sugi Predict

Sugi Predict / Compounds / Leuprolide

Leuprolide

Leuprolide

SCHEMBL177978

CC(=O)O.CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1

nearest known ligand 0.87

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GNRHR

The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ GNRHR known ✓ P30968 2/20 0.84
▸ ABCC2 Q92887 1/20 0.87
▸ PTGS1 P23219 1/20 0.78
▸ APLNR P35414 5/20 0.65
▸ CXCR4 P61073 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leuprolide SCHEMBL570851 1.00 ABCC2 (0.87) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL847084 1.00 ABCC2 (0.87) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL3174 1.00 ABCC2 (0.87) ABCC2GNRHRPTGS1APLNRCXCR4
Deslorelin SCHEMBL1649660 0.99 GNRHR (0.86) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL10061885 0.99 GNRHR (0.86) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL21540132 0.99 GNRHR (0.86) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL4585 0.99 GNRHR (0.86) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL7751433 0.99 GNRHR (0.86) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL4414320 0.98 ABCC2 (0.84) ABCC2GNRHRPTGS1APLNRCXCR4
Leuprolide SCHEMBL3915060 0.98 GNRHR (0.86) ABCC2GNRHRPTGS1APLNRCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007149103-A2 VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE KAISER DANIEL E (US) 2007-12-27 — — WO claimed
US-12037385-B2 Anti-polyubiquitin antibodies and methods of use GENENTECH, INC. (US) 2024-07-16 — — US disclosed
US-12030926-B2 Production of heteromultimeric proteins using mammalian cells GENENTECH, INC. (US) 2024-07-09 — — US disclosed
US-20240200146-A1 DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER GENENTECH INC (US) 2024-06-20 — — US disclosed
US-20240190967-A1 THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER GENENTECH INC (US) 2024-06-13 — — US disclosed
US-20240158513-A1 FC Variants and Methods for Their Production GENENTECH, INC. (US) 2024-05-16 — — US disclosed
WO-2024068968-A1 INHIBITION OF LUTEINIZING HORMONE (LH) ACTION AS TREATMENT OF PERIMENOPAUSAL AND POSTMENOPAUSAL SYMPTOMS AND COMPLICATIONS RIGSHOSPITALET (DK) 2024-04-04 — — WO disclosed
US-20240082151-A1 ORALLY IMPLANTABLE DRUG DELIVERY DEVICE OAK CREST INSTITUTE OF SCIENCE 2024-03-14 — — US disclosed
US-20240067709-A1 Methods and Compositions for Targeting Polyubiquitin GENENTECH, INC. (US) 2024-02-29 — — US disclosed
US-11912773-B2 Fc variants and methods for their production GENENTECH, INC. (US) 2024-02-27 — — US disclosed
US-20050272120-A1 Compositions and methods for the diagnosis and treatment of tumor GENENTECH, INC. (US) 2005-12-08 — — US disclosed
US-20050170368-A1 Compositions and methods for the diagnosis and treatment of tumor GENENTECH, INC. (US) 2005-08-04 — — US disclosed
US-20050106667-A1 Variant complementary determining regions for use in identifying antigen binding polypeptides; mimetics; direceted protein evolution GENENTECH, INC 2005-05-19 — — US disclosed
US-20050090514-A1 Trp-p8 active compounds and therapeutic treatment methods GENENTECH, INC. 2005-04-28 — — US disclosed
WO-2000077590-A9 APPARATUS FOR CALCULATING TIME PERIODS AND FUTURE DATES CRAIG H RANDALL (US) 2005-04-14 — — WO disclosed
WO-2005012531-A2 ANTIBODY CDR POLYPEPTIDE SEQUENCES WITH RESTRICTED DIVERSITY GENENTECH, INC. (US) 2005-02-10 — — WO disclosed
WO-2005002582-A2 TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS GENENTECH, INC. (US) 2005-01-13 — — WO disclosed
WO-2005003154-A2 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR GENENTECH, INC. (US) 2005-01-13 — — WO disclosed
US-20010053762-A1 METHOD OF TREATING REPRODUCTIVE DISORDERS MAACK CHRISTOPHER A (US) 2001-12-20 — — US disclosed
EP-0723453-B1 METHOD OF TREATING REPRODUCTIVE DISORDERS CELTRIX PHARMA (US) 2000-03-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067709-A1 Methods and Compositions for Targeting Polyubiquitin PSMG3, STUB1, USP47 GNRHR 3316/4885ABCC2 4355/4885PTGS1 4824/4885
US-20050090514-A1 Trp-p8 active compounds and therapeutic treatment methods TSG101, TP53, BAX GNRHR 2461/4885ABCC2 2988/4885PTGS1 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.